Medtronic Leaders to Address Investors at Upcoming Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 29 2025
0mins
Source: Newsfilter
Medtronic Investor Conferences Announcement
Upcoming Conferences: Medtronic plc will participate in several investor conferences in September 2025, including the Wells Fargo Healthcare Conference on September 4, the Morgan Stanley Global Healthcare Conference on September 8, the Deutsche Bank Healthcare Summit on September 10, and the BofA Global Research Healthcare Conference on September 24.
Key Speakers: The conferences will feature prominent executives such as Geoff Martha (Chairman and CEO), Thierry Piéton (CFO), and Greg Smith (EVP, Enterprise Operations), who will address questions regarding the company.
Webcast Availability: Each conference session will be available via live webcast, with archived sessions accessible later on Medtronic's investor relations website.
About Medtronic
Company Overview: Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company with over 95,000 employees across more than 150 countries.
Mission and Impact: The company's mission is to alleviate pain, restore health, and extend life, addressing 70 health conditions through various technologies, including cardiac devices, surgical robotics, and patient monitoring systems.
Innovative Approach: Medtronic emphasizes its commitment to innovative solutions that transform lives, claiming to impact two individuals every second, highlighting its focus on insight-driven care and improved health outcomes.
Contact Information
- Media and Investor Relations: For further inquiries, contacts include Erika Winkels for public relations and Ryan Weispfenning for investor relations, both reachable at Medtronic's office.
Forward-Looking Statements
- Risk Disclaimer: The announcement includes a note on forward-looking statements, indicating that actual results may differ from anticipated outcomes due to various risks and uncertainties.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 79.270
Low
102.00
Averages
111.76
High
120.00
Current: 79.270
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opportunities in Dividend Stocks Amid Economic Tensions
- Economic Impact: Despite witnessing the largest IPO in history and a booming AI sector, serious economic and geopolitical tensions could significantly dampen Wall Street's excitement, particularly with rising inflation and recession warnings.
- Pfizer's Challenges and Opportunities: Pfizer faces challenges from patent cliffs, especially for its anticoagulant Eliquis, but has significantly expanded its pipeline through acquisitions and new product development, particularly in oncology and weight loss, which are expected to support future financial performance.
- Medtronic's Long-Term Appeal: Although Medtronic's latest earnings report missed Wall Street estimates and it faces challenges from tariffs and macroeconomic factors, its extensive product lineup across multiple therapeutic areas and a 48-year streak of increasing dividends make it an attractive long-term investment choice.
- Dividend Yield Analysis: Pfizer offers a dividend yield of 6.8%, while Medtronic provides a yield of 3.63%, making both companies viable options for investors seeking stable income in the current economic climate.
See More
Investment Outlook for Healthcare Stocks
- Attractive Dividend Yields: Pfizer (PFE) and Medtronic (MDT) offer forward dividend yields of 6.8% and 3.63%, respectively, providing investors with stable income sources amid rising inflation and potential recession risks, which is crucial in the current economic uncertainty.
- Pfizer's Product Pipeline: Pfizer is developing the anti-obesity drug MET-097i and several cancer treatments, including PF'4404, which are expected to significantly enhance the company's financial performance in the coming years, helping it navigate challenges posed by patent expirations.
- Medtronic's Market Opportunities: Medtronic's Hugo robotic-assisted surgery system has received U.S. clearance, which is anticipated to drive sales growth in an underpenetrated market, although the company faces short-term cost pressures and margin squeezes.
- Long-Term Growth Potential: Both companies possess strong product portfolios and market demand, with Pfizer and Medtronic's dividend growth records and future innovation capabilities making them attractive long-term investments in a diversified portfolio.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Dividend Stocks as a Risk Reduction Strategy
- Stability in Healthcare: Medtronic, a leader in the medical device industry, shows an 8% revenue growth in its latest fiscal year, and with a dividend yield of 3.6% and a low P/E ratio of 13, it presents an attractive investment opportunity amid market volatility.
- REIT Advantages: Realty Income achieved a 9% revenue growth to $5.7 billion in 2025, and its diverse tenant mix reduces risk, making it appealing for risk-averse investors with the highest dividend yield of 5.2% on this list.
- Energy Stock Resilience: ExxonMobil, a giant in the oil and gas sector, has a dividend yield of 2.9% and saw its stock surge 26% over the past year, demonstrating its stability as it rose 80% when the S&P 500 fell by 19% in 2022, showcasing its risk mitigation capabilities.
- Portfolio Diversification: Investing in these low-volatility stocks allows investors to effectively reduce exposure to market fluctuations, particularly in the context of rising valuations, thereby enhancing the resilience of their investment portfolios.
See More
Recommended Dividend Stocks for Stable Income
- Healthcare Industry Leader: Medtronic, a leading medical device manufacturer, benefits from ongoing product demand, with its latest fiscal year showing an 8% revenue growth, indicating stable growth trends, while its dividend yield stands at 3.6%, significantly higher than the S&P 500's 1.1%.
- Advantages of REITs: Realty Income achieved a 9% revenue growth in 2025, reaching $5.7 billion, and by maintaining a diverse tenant mix, it mitigates risk, offering a dividend yield of 5.2% and consistently increasing dividends, which boosts investor confidence.
- Stability of Oil Giants: ExxonMobil, known for its 2.9% dividend yield and a beta of just 0.15, indicates low sensitivity to market fluctuations, with a 26% stock price increase over the past year, showcasing its resilience during market downturns, making it an ideal choice for portfolio diversification.
- Risk Management in Portfolios: Amid increasing market volatility, investing in these low-volatility dividend stocks not only reduces investment risk but also provides stable cash flow, making them suitable for risk-averse investors seeking long-term returns.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Opportunities in Dividend Stocks Amid Economic Tensions
- Economic Impact: Despite witnessing the largest IPO in history and a booming AI sector, serious economic and geopolitical tensions could significantly dampen Wall Street's excitement, particularly with rising inflation and recession warnings.
- Pfizer's Challenges and Opportunities: Pfizer faces challenges from patent cliffs, especially for its anticoagulant Eliquis, but has significantly expanded its pipeline through acquisitions and new product development, particularly in oncology and weight loss, which are expected to support future financial performance.
- Medtronic's Long-Term Appeal: Although Medtronic's latest earnings report missed Wall Street estimates and it faces challenges from tariffs and macroeconomic factors, its extensive product lineup across multiple therapeutic areas and a 48-year streak of increasing dividends make it an attractive long-term investment choice.
- Dividend Yield Analysis: Pfizer offers a dividend yield of 6.8%, while Medtronic provides a yield of 3.63%, making both companies viable options for investors seeking stable income in the current economic climate.
See More
Investment Outlook for Healthcare Stocks
- Attractive Dividend Yields: Pfizer (PFE) and Medtronic (MDT) offer forward dividend yields of 6.8% and 3.63%, respectively, providing investors with stable income sources amid rising inflation and potential recession risks, which is crucial in the current economic uncertainty.
- Pfizer's Product Pipeline: Pfizer is developing the anti-obesity drug MET-097i and several cancer treatments, including PF'4404, which are expected to significantly enhance the company's financial performance in the coming years, helping it navigate challenges posed by patent expirations.
- Medtronic's Market Opportunities: Medtronic's Hugo robotic-assisted surgery system has received U.S. clearance, which is anticipated to drive sales growth in an underpenetrated market, although the company faces short-term cost pressures and margin squeezes.
- Long-Term Growth Potential: Both companies possess strong product portfolios and market demand, with Pfizer and Medtronic's dividend growth records and future innovation capabilities making them attractive long-term investments in a diversified portfolio.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Dividend Stocks as a Risk Reduction Strategy
- Stability in Healthcare: Medtronic, a leader in the medical device industry, shows an 8% revenue growth in its latest fiscal year, and with a dividend yield of 3.6% and a low P/E ratio of 13, it presents an attractive investment opportunity amid market volatility.
- REIT Advantages: Realty Income achieved a 9% revenue growth to $5.7 billion in 2025, and its diverse tenant mix reduces risk, making it appealing for risk-averse investors with the highest dividend yield of 5.2% on this list.
- Energy Stock Resilience: ExxonMobil, a giant in the oil and gas sector, has a dividend yield of 2.9% and saw its stock surge 26% over the past year, demonstrating its stability as it rose 80% when the S&P 500 fell by 19% in 2022, showcasing its risk mitigation capabilities.
- Portfolio Diversification: Investing in these low-volatility stocks allows investors to effectively reduce exposure to market fluctuations, particularly in the context of rising valuations, thereby enhancing the resilience of their investment portfolios.
See More
Recommended Dividend Stocks for Stable Income
- Healthcare Industry Leader: Medtronic, a leading medical device manufacturer, benefits from ongoing product demand, with its latest fiscal year showing an 8% revenue growth, indicating stable growth trends, while its dividend yield stands at 3.6%, significantly higher than the S&P 500's 1.1%.
- Advantages of REITs: Realty Income achieved a 9% revenue growth in 2025, reaching $5.7 billion, and by maintaining a diverse tenant mix, it mitigates risk, offering a dividend yield of 5.2% and consistently increasing dividends, which boosts investor confidence.
- Stability of Oil Giants: ExxonMobil, known for its 2.9% dividend yield and a beta of just 0.15, indicates low sensitivity to market fluctuations, with a 26% stock price increase over the past year, showcasing its resilience during market downturns, making it an ideal choice for portfolio diversification.
- Risk Management in Portfolios: Amid increasing market volatility, investing in these low-volatility dividend stocks not only reduces investment risk but also provides stable cash flow, making them suitable for risk-averse investors seeking long-term returns.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
